NCT07166003 Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
| NCT ID | NCT07166003 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Lung Cancer, Non-Small Cell |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-04-20 |
| Primary Completion | 2027-02-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-04-20 with a primary completion date of 2027-02-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Eligibility Criteria
Inclusion Criteria: 1. Aged between 18 and 79 years; 2. Received at least two cycles of neoadjuvant immunotherapy; 3. ECOG performance status score of 0; 4. Complete clinical information including imaging data available. Exclusion Criteria: 1. Diagnosed with or suspected active autoimmune diseases; 2. Presence of EGFR/ALK sensitive mutations; 3. Pregnant or breastfeeding women; 4. Previous anti-tumor therapies including chemotherapy or radiotherapy; 5. History of organ transplantation or hematopoietic stem cell transplantation; 6. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema; 7. Uncontrolled diabetes mellitus; 8. Uncontrolled hypertension.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07166003 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 79 Years, studying Lung Cancer, Non-Small Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07166003 currently recruiting?
Yes, NCT07166003 is actively recruiting participants. Contact the research team at gaoshugeng@cicams.ac.cn for enrollment information.
Where is the NCT07166003 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07166003 clinical trial?
NCT07166003 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.